The US Food and Drug Administration has approved Eli Lilly’s once-weekly basal insulin, Onswik, for adults with type ​2 diabetes, the drugmaker said on Thursday, offering patients ‌an alternative to ...

The FDA just handed Eli Lilly a new diabetes approval, but the real debate is whether a once-weekly insulin needle moves the ...

Approval marks the second once-weekly basal insulin for this population ...

Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

People with type 2 diabetes (T2D) who began using continuous glucose monitoring (CGM) while receiving basal insulin had a 44% ...

A reported Spanish consensus would make continuous glucose monitoring routine for some type 2 diabetes patients using basal ...

Adults with type 2 diabetes will have a new alternative to daily insulin injections now that the U.S. Food and Drug Administration (FDA) approved a new once-a-week insulin injection.

FDA authorization positions insulin efsitora as the second once-weekly basal insulin in the US, following insulin icodec, which achieves weekly delivery via albumin-binding depot pharmacology. QWINT ...

The FDA has approved once-weekly Onswik (insulin efsitora alfa-gobe) for adults with type 2 diabetes mellitus based on noninferior HbA1c reductions vs daily basal insulins across four phase 3 trials.

Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approval of Onswik? (insulin efsitora alfa-gobe), a once-weekly basal insulin, indicated along with diet and exercise to ...

DreaMed Diabetes has received FDA 510(K) clearance for MODI, a mobile app that uses CGM (continuous glucose monitoring) data ...